Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Jan Moritz Middeke, Julia M. Unglaub et al.|Blood Cancer Journal|2021Cited by 65
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patientsChristina Rautenberg, Friedrich Stölzel, Jan Moritz Middeke et al.|Blood Cancer Journal|2025Cited by 6
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid LeukemiaChristina Rautenberg, M. Middeke, Friedrich Stölzel et al.|Blood|2021Cited by 3
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemiaSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Haematologica|2024Cited by 1